Claims
- 1. A method for the treatment of a cancerous or pre-cancerous condition of the lung, esophagus or liver, comprising administering to a patient in need thereof an immunogen which induces antibodies in the patient against G17 and/or CCK-B/gastrin receptor which antibodies inhibit the binding of G17 to its receptor on pre-cancerous or cancerous cells.
- 2. A method for the treatment of a cancerous or pre-cancerous condition of the lung, liver or esophagus comprising administering to a patient anti-G17 antibodies and/or anti-CCK-B/gastrin receptor antibodies which selectively neutralize the peptide hormone G17 in vivo or inhibit activation of the receptor in vivo.
- 3. A method for the treatment of a cancerous or pre-cancerous condition of the lung, liver or esophagus, comprising administering to a patient in need thereof an immunogen which is capable of eliciting a sufficient titer of antibodies in the patient which selectively bind and neutralize the patient's own G17.
- 4. A method for the treatment of a cancerous or pre-cancerous condition of the lung, liver or esophagus, comprising administering to a patient in need thereof an immunogen which is capable of eliciting a sufficient titer of antibodies in the patient which selectively bind and neutralize the CCK-B/gastrin receptor molecules expressed on cancerous or pre-cancerous cells in the lung, liver or esophagus.
- 5. The method of claim 2, 3 or 4, wherein the condition is a lung cancer, wherein the lung cancer is at least partially gastrin-promoted.
- 6. The method of claim 5, wherein the lung cancer originated in the lung.
- 7. The method of claim 5, wherein the lung cancer has a metastatic origin.
- 8. The method of claim 7, wherein the metastatic origin of the lung cancer is a gastrointestinal malignancy.
- 9. The method of claim 2, 3 or 4, wherein the condition is liver cancer.
- 10. The method of claim 9, wherein the liver cancer originated in the liver.
- 11. The method of claim 9, wherein the liver cancer has a metastatic origin.
- 12. The method of claim 11, wherein the metastatic origin of the liver cancer is a gastrointestinal malignancy.
- 13. The method of claim 2, 3 or 4, wherein the condition is a pre-cancerous condition.
- 14. The method of claim 13 wherein the condition is Barrett's esophagus.
- 15. The method of claim 14 wherein the treatment prevents or delays progression of the Barrett's esophagus to a cancerous state.
- 16. A method for treating the growth of a gastrin-induced tumor or pre-cancerous lesion of the lung, liver or esophagus in a patient by selectively neutralizing the peptide hormone G17 in vivo, which comprises administering to the patient anti-G17 antibodies which bind to an epitope located on the amino terminus of G17 so as to inhibit the binding of G17 to its physiological receptor on the tumor.
- 17. A method for the treatment of a gastrin-induced disorder of the lung, liver or esophagus comprising administering to a patient antibodies which selectively bind with heptadecagastrin (G17).
- 18. A method for the treatment of a cancerous or pre-cancerous condition of the lung, liver or esophagus disorder in mammal which comprises administering a therapeutic agent which neutralizes the hormone G17 in vivo.
- 19. A method for the treatment of a cancerous or pre-cancerous condition of the lung, liver or esophagus, comprising administering to a patient in need thereof an immunogen which raises antibodies in the patient against the CCK-B/gastrin receptor, wherein the antibodies block the activation of the gastrin receptor which results by the binding of gastrin to the receptor.
- 20. A method for the treatment of a cancerous or pre-cancerous condition of the lung, liver or esophagus comprising administering to a patient anti-CCK-B/gastrin receptor antibodies which block the activation of the gastrin receptor which results by the binding of gastrin to the receptor.
- 21. The method of claim 22 or 23 further comprising administering an immunogen which raises antibodies against G17.
- 22. The method of claim 22 or 23 further comprising administering anti-G17 antibodies which selectively neutralize the peptide hormone G17 in vivo.
- 23. The method according to claim 1 or 2, wherein the condition is a cancer of the esophagus.
- 24. The method according to claim 26, wherein the cancer is an adenocarcinoma.
- 25. The method of claim 1, further comprising an adjuvant chemotherapy comprising administration of cisplatin, carboplatin, oxaloplatin, irinotecan, topotecan, 5-fluorouracil, leucovorin, gemcitabine, and/or a taxane.
- 26. A method for the treatment of non-small cell lung cancer, comprising the steps of:
(a) actively and/or passively immunizing a patient against G17 gastrin and/or the CCK-B/gastrin receptor, wherein the antibodies provided and/or induced inhibit the binding of G17 to its receptor on pre-cancerous cells and/or inhibit activation of the receptor; and (b) concomitantly or sequentially administering an effective amount of docetaxel to the patient.
Parent Case Info
[0001] This application claims priority from the provisional patent application serial No. 60/303,868 filed Jul. 9, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60303868 |
Jul 2001 |
US |